Clinical trial locations
- Austria
- Germany
- Poland
- Sweden
Study on the Effects of AD04 and Placebo in Patients with Early Alzheimer's Disease
This trial, conducted in Austria and Poland, tests whether AD04 can slow the progression of early Alzheimer's disease. The study compares AD04 with a placebo over six months, evaluating improvements in cognitive abilities, daily functioning, and overall health.
Main inclusion criteria: Participants must be between 50 and 85 years old with a partner or caregiver who knows them well and has at least 10 hours of weekly contact. Those of childbearing potential must use effective birth control. Participants must have a diagnosis of probable Alzheimer's disease with a Mini-Mental State Examination score between 22 and 30. Brain MRI must show shrinkage in specific areas, or cerebrospinal fluid tests must show patterns related to Alzheimer's disease. Memory tests must indicate problems related to the hippocampus. Physical examination results, including vision and hearing, must be within acceptable ranges, and participants must score 4 or less on the Hachinski Ischemia Scale.
Main exclusion criteria: The study excludes patients with other serious health conditions that might interfere with the study, those participating in another trial, patients with recent or planned surgery, history of severe allergic reactions, inability to comply with procedures, history of drug or alcohol abuse, pregnancy or breastfeeding, unstable mental health conditions, diagnosis of a different type of dementia, or history of stroke or significant brain injury.
Focus and goals: Participants receive either AD04 or placebo through subcutaneous injections under the skin. The study monitors cognitive function, daily activities, and overall well-being through regular assessments including brain imaging. Neither participants nor researchers know who receives the actual treatment, ensuring unbiased results.
Investigational drugs: AD04 is an investigational medication containing aluminum hydroxide, administered as an injection solution. It targets specific pathways in the brain involved in disease progression, though the exact mechanism is still being researched. The goal is to slow down the worsening of memory, thinking, and behavioral symptoms in early Alzheimer's disease.
Summary
The three ongoing clinical trials represent different approaches to addressing mixed dementia and related conditions. Two of the studies focus on advanced diagnostic imaging techniques using PET scans to detect amyloid plaques and tau proteins in the brain, which are hallmarks of Alzheimer's disease. These diagnostic trials are being conducted in Sweden and Germany and aim to improve early detection and accuracy of dementia diagnosis.
The third trial, conducted in Austria and Poland, takes a different approach by testing a potential treatment called AD04 that aims to slow disease progression in patients with early Alzheimer's disease. All three studies emphasize the importance of early intervention and accurate diagnosis in managing these complex neurodegenerative conditions.
The trials reflect growing international collaboration in dementia research, with studies spanning multiple European countries. The focus on both diagnostic accuracy and therapeutic intervention demonstrates the multifaceted approach needed to address the challenges posed by these debilitating conditions.
Germany